PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(03): 380-382
DOI: 10.4103/ijmpo.ijmpo_70_16
Case Report

Uncommon Adverse Effects of Commonly Used Chemotherapeutic Agents in Medical Oncology Practice: A Series of Two Cases of Hand‑Foot Syndrome

Autor*innen

  • Waseem Dar

    Department of Medical Oncology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India

  • Mir Hussain

    Department of Medical Oncology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India

  • Sheikh Aijaz Aziz

    Department of Medical Oncology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India

  • Gul Mohammad

    Department of Medical Oncology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India

  • Burhan Wani

    Department of Medical Oncology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India

  • Muzamil Latief

    Department of Medical Oncology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India

Financial support and sponsorship Nil.
Weitere Informationen
Auch verfügbar auf
 als PDF herunterladen Lizenzen und Reprints

Abstract

Chemotherapy has an increasing potential for cure and palliation of most forms of cancer in different stages. However, its use is associated with a multitude of side effects some very common and few very rare. We present two patients of metastatic nonsmall lung cancer who had severe forms of hand-foot syndrome with two different classes of antineoplastic drugs and have to discontinue chemotherapy.

Keywords

Chemotherapy - cancer - hand-foot syndrome - palliation


Publikationsverlauf

Artikel online veröffentlicht:
04. Juli 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Chu CY, Yang CH, Yang CY, Hsiao GH, Chiu HC. Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol 2000;142:808-11.
  • 2 Schrijvers D, Van Den Brande J, Vermorken JB. Supravenous discoloration of the skin due to docetaxel treatment. Br J Dermatol 2000;142:1069-70.
  • 3 Eich D, Scharffetter-Kochanek K, Eich HT, Tantcheva-Poor I, Krieg T. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol 2002;25:599-602.
  • 4 Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 2007;11:238-46.
  • 5 Smith GA. Current status of vinorelbine for breast cancer. Oncology (Williston Park) 1995;9:767-73.
  • 6 Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994;21 5 Suppl 10:42-6.
  • 7 Wargin WA, Lucas VS. The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol 1994;21 5 Suppl 10:21-7.
  • 8 Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 1998;82:965-9.
  • 9 Vaishampayan U, Parchment RE, Jasti BR, Hussain M. Taxanes: An overview of the pharmacokinetics and pharmacodynamics. Urology 1999;54 6A Suppl:22-9.
  • 10 Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998;55:5-30.
  • 11 Docetaxel Drug Information Website. Available from: http://www.taxotere.com/oncology/about_Taxotere/mechanism_of_action.aspx. [Last accessed on 2016 Apr 20].
  • 12 Chew L, Chuen VS. Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract 2009;15:29-34.
  • 13 Zimmerman GC, Keeling JH, Lowry M, Medina J, Von Hoff DD, Burris HA. Prevention of docetaxel-induced erythrodysesthesia with local hypothermia. J Natl Cancer Inst 1994;86:557-8.
  • 14 Milano G, Etienne-Grimaldi MC, Mari M, Lassalle S, Formento JL, Francoual M, et al. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 2008;66:88-95.
  • 15 Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, et al. Hand-foot skin reaction in patients treated with sorafenib: A clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158:592-6.